NeoGenomics (NEO) Competitors

$8.37 +0.13 (+1.58%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$8.26 -0.10 (-1.25%)

As of 07:19 AM Eastern

NEO vs. FTDR, HRI, HNGE, XMTR, and WPP

Should you buy NeoGenomics stock or one of its competitors? MarketBeat compares NeoGenomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeoGenomics include Frontdoor (FTDR), Herc (HRI), Hinge Health (HNGE), Xometry (XMTR), and WPP (WPP). These companies are all part of the "business services" industry.

How does NeoGenomics compare to Frontdoor?

NeoGenomics (NASDAQ:NEO) and Frontdoor (NASDAQ:FTDR) are both business services companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, NeoGenomics and NeoGenomics both had 3 articles in the media. Frontdoor's average media sentiment score of 0.52 beat NeoGenomics' score of 0.22 indicating that Frontdoor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Frontdoor	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

NeoGenomics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Frontdoor has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Frontdoor has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Frontdoor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	1.50	-$108.03M	-$0.77	N/A
Frontdoor	$2.09B	2.13	$255M	$3.49	18.18

Frontdoor has a net margin of 12.22% compared to NeoGenomics' net margin of -13.30%. Frontdoor's return on equity of 118.62% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-13.30%	-2.80%	-1.72%
Frontdoor	12.22%	118.62%	14.20%

NeoGenomics currently has a consensus price target of $13.86, suggesting a potential upside of 65.56%. Frontdoor has a consensus price target of $68.60, suggesting a potential upside of 8.13%. Given NeoGenomics' higher probable upside, equities research analysts plainly believe NeoGenomics is more favorable than Frontdoor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Frontdoor	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

98.5% of NeoGenomics shares are held by institutional investors. 1.1% of NeoGenomics shares are held by company insiders. Comparatively, 1.6% of Frontdoor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Frontdoor beats NeoGenomics on 12 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Herc?

Herc (NYSE:HRI) and NeoGenomics (NASDAQ:NEO) are both business services companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, NeoGenomics had 1 more articles in the media than Herc. MarketBeat recorded 3 mentions for NeoGenomics and 2 mentions for Herc. Herc's average media sentiment score of 0.78 beat NeoGenomics' score of 0.22 indicating that Herc is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Herc	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.1% of Herc shares are owned by institutional investors. Comparatively, 98.5% of NeoGenomics shares are owned by institutional investors. 2.2% of Herc shares are owned by company insiders. Comparatively, 1.1% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Herc presently has a consensus price target of $165.67, suggesting a potential upside of 23.53%. NeoGenomics has a consensus price target of $13.86, suggesting a potential upside of 65.56%. Given NeoGenomics' stronger consensus rating and higher possible upside, analysts plainly believe NeoGenomics is more favorable than Herc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Herc	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42

Herc has higher revenue and earnings than NeoGenomics. Herc is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Herc	$4.38B	1.02	$1M	-$0.27	N/A
NeoGenomics	$727.33M	1.50	-$108.03M	-$0.77	N/A

Herc has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market.

Herc has a net margin of -0.11% compared to NeoGenomics' net margin of -13.30%. Herc's return on equity of 10.72% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Herc	-0.11%	10.72%	1.49%
NeoGenomics	-13.30%	-2.80%	-1.72%

Summary

Herc beats NeoGenomics on 9 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Hinge Health?

NeoGenomics (NASDAQ:NEO) and Hinge Health (NYSE:HNGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

NeoGenomics has a net margin of -13.30% compared to Hinge Health's net margin of -78.95%. NeoGenomics' return on equity of -2.80% beat Hinge Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-13.30%	-2.80%	-1.72%
Hinge Health	-78.95%	-310.62%	-71.08%

NeoGenomics currently has a consensus target price of $13.86, indicating a potential upside of 65.56%. Hinge Health has a consensus target price of $67.40, indicating a potential upside of 22.89%. Given NeoGenomics' higher probable upside, research analysts plainly believe NeoGenomics is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Hinge Health	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.95

In the previous week, Hinge Health had 7 more articles in the media than NeoGenomics. MarketBeat recorded 10 mentions for Hinge Health and 3 mentions for NeoGenomics. Hinge Health's average media sentiment score of 0.86 beat NeoGenomics' score of 0.22 indicating that Hinge Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hinge Health	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of NeoGenomics shares are owned by institutional investors. 1.1% of NeoGenomics shares are owned by company insiders. Comparatively, 18.9% of Hinge Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	1.50	-$108.03M	-$0.77	N/A
Hinge Health	$587.86M	7.22	-$528.26M	-$12.34	N/A

Summary

NeoGenomics and Hinge Health tied by winning 8 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Xometry?

Xometry (NASDAQ:XMTR) and NeoGenomics (NASDAQ:NEO) are both business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Xometry has a net margin of -7.01% compared to NeoGenomics' net margin of -13.30%. NeoGenomics' return on equity of -2.80% beat Xometry's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xometry	-7.01%	-4.37%	-1.71%
NeoGenomics	-13.30%	-2.80%	-1.72%

Xometry has higher revenue and earnings than NeoGenomics. Xometry is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xometry	$740.80M	6.15	-$61.74M	-$1.02	N/A
NeoGenomics	$727.33M	1.50	-$108.03M	-$0.77	N/A

97.3% of Xometry shares are owned by institutional investors. Comparatively, 98.5% of NeoGenomics shares are owned by institutional investors. 9.1% of Xometry shares are owned by insiders. Comparatively, 1.1% of NeoGenomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Xometry had 13 more articles in the media than NeoGenomics. MarketBeat recorded 16 mentions for Xometry and 3 mentions for NeoGenomics. Xometry's average media sentiment score of 0.61 beat NeoGenomics' score of 0.22 indicating that Xometry is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xometry	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xometry has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

Xometry presently has a consensus target price of $76.00, suggesting a potential downside of 13.60%. NeoGenomics has a consensus target price of $13.86, suggesting a potential upside of 65.56%. Given NeoGenomics' higher possible upside, analysts plainly believe NeoGenomics is more favorable than Xometry.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xometry	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42

Summary

Xometry beats NeoGenomics on 9 of the 15 factors compared between the two stocks.

How does NeoGenomics compare to WPP?

WPP (NYSE:WPP) and NeoGenomics (NASDAQ:NEO) are both business services companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

WPP has a net margin of 0.00% compared to NeoGenomics' net margin of -13.30%. WPP's return on equity of 0.00% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WPP	N/A	N/A	N/A
NeoGenomics	-13.30%	-2.80%	-1.72%

4.3% of WPP shares are held by institutional investors. Comparatively, 98.5% of NeoGenomics shares are held by institutional investors. 1.0% of WPP shares are held by insiders. Comparatively, 1.1% of NeoGenomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

WPP has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

NeoGenomics has a consensus price target of $13.86, suggesting a potential upside of 65.56%. Given NeoGenomics' stronger consensus rating and higher possible upside, analysts clearly believe NeoGenomics is more favorable than WPP.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WPP	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42

NeoGenomics has lower revenue, but higher earnings than WPP.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WPP	$13.55B	0.30	-$283.52M	N/A	N/A
NeoGenomics	$727.33M	1.50	-$108.03M	-$0.77	N/A

In the previous week, NeoGenomics had 1 more articles in the media than WPP. MarketBeat recorded 3 mentions for NeoGenomics and 2 mentions for WPP. WPP's average media sentiment score of 0.36 beat NeoGenomics' score of 0.22 indicating that WPP is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WPP	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NeoGenomics beats WPP on 9 of the 14 factors compared between the two stocks.

Get NeoGenomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEO vs. The Competition

Export

Metric	NeoGenomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.07B	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-10.87	18.13	20.64	25.23
Price / Sales	1.50	289.87	554.85	79.36
Price / Cash	24.59	55.27	27.48	37.30
Price / Book	1.29	6.57	9.66	6.63
Net Income	-$108.03M	$24.35M	$3.56B	$335.59M
7 Day Performance	-4.34%	-2.53%	-1.65%	-1.20%
1 Month Performance	0.24%	-3.55%	-2.60%	-1.16%
1 Year Performance	3.85%	53.51%	30.07%	28.10%

NeoGenomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEO NeoGenomics	2.9505 of 5 stars	$8.37 +1.6%	$13.86 +65.6%	+3.2%	$1.07B	$727.33M	N/A	2,500
FTDR Frontdoor	2.1147 of 5 stars	$63.78 -1.3%	$68.60 +7.6%	+14.7%	$4.54B	$2.09B	18.28	2,034
HRI Herc	4.076 of 5 stars	$136.30 +2.0%	$165.67 +21.5%	-2.3%	$4.46B	$4.38B	N/A	9,600	Positive News Dividend Announcement
HNGE Hinge Health	3.7551 of 5 stars	$54.69 -2.4%	$67.40 +23.2%	N/A	$4.41B	$587.86M	N/A	1,437
XMTR Xometry	1.9949 of 5 stars	$80.74 +0.9%	$71.88 -11.0%	+156.5%	$4.15B	$686.63M	N/A	1,174

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEO) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeoGenomics (NEO) Competitors

NEO vs. FTDR, HRI, HNGE, XMTR, and WPP

How does NeoGenomics compare to Frontdoor?

Summary

How does NeoGenomics compare to Herc?

Summary

How does NeoGenomics compare to Hinge Health?

Summary

How does NeoGenomics compare to Xometry?

Summary

How does NeoGenomics compare to WPP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeoGenomics (NEO) Competitors

NEO vs. FTDR, HRI, HNGE, XMTR, and WPP

How does NeoGenomics compare to Frontdoor?

Does the media favor NEO or FTDR?

Which has more risk & volatility, NEO or FTDR?

Which has preferable valuation & earnings, NEO or FTDR?

Is NEO or FTDR more profitable?

Do analysts rate NEO or FTDR?

Do insiders and institutionals have more ownership in NEO or FTDR?

Summary

How does NeoGenomics compare to Herc?

Does the media refer more to HRI or NEO?

Do institutionals and insiders have more ownership in HRI or NEO?

Do analysts prefer HRI or NEO?

Which has higher valuation & earnings, HRI or NEO?

Which has more risk & volatility, HRI or NEO?

Is HRI or NEO more profitable?

Summary

How does NeoGenomics compare to Hinge Health?

Is NEO or HNGE more profitable?

Do analysts prefer NEO or HNGE?

Does the media refer more to NEO or HNGE?

Do insiders and institutionals hold more shares of NEO or HNGE?

Which has better valuation and earnings, NEO or HNGE?

Summary

How does NeoGenomics compare to Xometry?

Is XMTR or NEO more profitable?

Which has stronger valuation and earnings, XMTR or NEO?

Do insiders & institutionals hold more shares of XMTR or NEO?

Does the media prefer XMTR or NEO?

Which has more volatility and risk, XMTR or NEO?

Do analysts prefer XMTR or NEO?

Summary

How does NeoGenomics compare to WPP?

Is WPP or NEO more profitable?

Do insiders and institutionals have more ownership in WPP or NEO?

Which has more volatility & risk, WPP or NEO?

Do analysts prefer WPP or NEO?

Which has stronger earnings & valuation, WPP or NEO?

Does the media favor WPP or NEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools